Company intelligence / Profile preview

Imagene

Miami, Florida, United Statesimagene-ai.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Imagene has demonstrated the ability to rapidly identify actionable cancer biomarkers from biopsy images using its AI-powered platform. For example, its LungOI panel can predict NSCLC biomarkers within minutes, enabling same-day treatment decisions that would otherwise take weeks. This technology has been shown to improve patient outcomes by facilitating timely targeted therapy initiation in urgent cases.

Therapeutic areas: Oncology
Modalities: Artificial intelligence-driven analysis of biopsy images and omics data for biomarker discovery and diagnostics
Industry: Digital Health Medical Devices

Partnerships

Tempus AI – partnership to offer rapid lung cancer biomarker profiling across the US integrating Imagene’s models into clinical workflows.

Beyond the preview

Go deeper on Imagene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imagene.

Explore the full profile